ReShape Lifesciences Inc. (OBLN) [Rocket]

In millions, except per share items	Jun-30-23	Mar-31-23	Sep-30-22	Jun-30-22	Mar-31-22	Dec-31-21	Sep-30-21	Jun-30-21
	10-Q	10-Q	10-Q	10-Q	10-Q	10-K	10-Q	10-Q
Revenue			11.3	12.2	12.8	13.6	13.7	13.6
Revenue growth			-17.5%	-10.2%	9.3%	46.4%	98.9%	276.4%
Cost of revenue			4.3	5.2	5.5	5.3	5.5	5.2
Gross profit			7.0	7.0	7.3	8.3	8.2	8.4
Gross margin			61.9%	57.6%	56.8%	61.4%	60.1%	61.6%

Operating expenses:
Sales and marketing			33.4	42.4	38.2	33.6	29.2	17.3
General and administrative			18.5	26.6	25.6	24.4	21.8	12.2
Research and development			2.4	3.3	2.7	2.5	3.1	2.4
(Gain) loss on disposal of assets, net				0.4
Total operating expenses			71.8	74.9	69.6	64.8	32.4	19.7
Operating loss			-64.8	-67.9	-62.4	-56.5	-24.1	-11.3
Operating margin			-575.2%	-557.4%	-486.4%	-415.4%	-176.7%	-83.6%

Other expense (income), net:
Interest income, net			0.0	0.0	0.2	-0.4	-0.8	-1.6
(Gain) loss on foreign currency exchange, net			0.5	0.1	-0.2	-0.2	-0.5	-0.5
Other				0.0	0.0
Loss before income tax provision			-65.3	-70.8	-65.3	-62.0	-35.1	-22.6
Income tax expense			-0.5	-0.1	-0.1	-0.1	-0.1	-0.1
Net loss			-64.8	-70.7	-65.2	-61.9	-35.0	-22.5

Net loss per share - basic and diluted:
Net loss per share - basic (in dollars per share)			($49.33)	($49.85)	($26.26)	($5.63)	($5.32)	($5.60)
Net loss per share - diluted (in dollars per share)			($49.33)	($49.85)	($26.26)	($5.63)	($5.32)	($5.60)

Shares used to compute basic net loss per share (in shares)			8.9	7.6	8.6	9.5	7.4	4.1
Shares used to compute diluted net loss per share (in shares)			8.9	7.6	8.6	9.5	7.4	4.1